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Although dendritic cell (DC) dysfunction in cancer is a
well-recognized consequence of cancer-associated
inflammation that contributes to immune evasion,
the mechanisms that drive this process remain
elusive. Here, we show the critical importance of tu-
mor-derived TLR2 ligands in the generation of immu-
nosuppressive IL-10-producing human and mouse
DCs. TLR2 ligation induced two parallel synergistic
processes that converged to activate STAT3: stimu-
lation of autocrine IL-6 and IL-10 and upregulation of
their respective cell surface receptors, which low-
ered the STAT3 activation threshold. We identified
versican as a soluble tumor-derived factor that acti-
vates TLR2 in DCs. TLR2 blockade in vivo improved
intra-tumor DC immunogenicity and enhanced the
efficacy of immunotherapy. Our findings provide a
basis for understanding the molecular mechanisms
of DC dysfunction in cancer and identify TLR2 as a
relevant therapeutic target to improve cancer immu-
notherapy.INTRODUCTION
Inflammation is an integral feature of many cancers (Hanahan
and Weinberg, 2011). Infiltrating leukocytes, mesenchymal stro-
mal cells, extracellular matrix (ECM), and various cytokines and
growth factors create a complex dynamic microenvironment
that influences cancer growth, metastases, and prognosis
(Coussens et al., 2013; Galon et al., 2006). The drivers of inflam-
mation remain poorly understood, although evidence points to
the importance of endogenous ‘‘danger signals’’ released from
stressed and dying cancer cells and components of the ECM
that activate pattern recognition receptors—such as the Toll-
like receptors (TLRs) and nucleotide-binding oligomerization
domain (NOD)-like receptors—and downstream signaling cas-
cades (Chen and Nun˜ez, 2010; Iwasaki and Medzhitov, 2010).
In addition, TLR agonists produced by commensal bacteria in
the gut have been shown recently to enhance the cytotoxic ac-Cell Reptivity of tumor-associated myeloid cells during chemotherapy
(Iida et al., 2013).
Dendritic cells (DCs) specialize in antigen capture, process-
ing, and presentation and provide a key link between innate
and adaptive immunity (Steinman, 2012). DCs prime naive tu-
mor-antigen-specific CD8+ T cells in lymphoid tissues, which
results in the generation of cytotoxic T lymphocytes (CTLs)
that migrate via the circulation into the tumor. In addition, recent
reports have shown that tumor DCs stimulate naive T cells
and CTL in situ, which appeared essential for the control of tu-
mor growth. Indeed, the cancer microenvironment has been
equated to a lymphoid organ (Zitvogel and Kroemer, 2014).
Cancer impairs the function of DCs, which contributes to inef-
fective anti-tumor CTL responses (Gabrilovich et al., 2012). DC
dysfunction in cancer is strongly associated with elevated
expression levels of cytokines including interleukin (IL)-6 and
IL-10, reduced expression of IL-12, and activation of signal
transducer and activator of transcription 3 (STAT3) (Gabrilovich,
2004; Yu et al., 2007). Cancers may also fail to support the gen-
eration or recruitment of DC subpopulations that are known to
have superior antigen cross-presentation activity, such as
CD103+ DCs (Broz et al., 2014). Efforts to further define these
mechanisms and their relationship to cancer-associated inflam-
mation have been hampered, however, by the poor understand-
ing of the origin of tumor DCs and their evolution within the
tumor microenvironment.
Common DC precursors (CDP), a defined bone marrow pro-
genitor dedicated to the DC lineage (Guilliams et al., 2014;
Merad et al., 2013; Naik et al., 2007; Onai et al., 2007, 2013),
produce circulating pre-conventional DCs (pre-cDCs) and plas-
macytoid DCs (pDCs) that are committed to become DCs in
lymphoid and non-lymphoid tissues in the mouse (Diao et al.,
2004, 2006; Liu et al., 2009; Meredith et al., 2012; Naik et al.,
2006; Satpathy et al., 2012; Schlitzer et al., 2015). A parallel
pathway exists in the human (Breton et al., 2015; Lee et al.,
2015). We reported that tumors recruit circulating pre-cDCs
through a CCL3-dependent mechanism where they generate
normal immunostimulatory cDCs that undergo several rounds
of cell division (Diao et al., 2010). Under the influence of the
cancer milieu, some cells differentiated into immunosuppres-
sive DCs and macrophages (Diao et al., 2011, 2012). IL-6 ap-
peared to regulate this process, although the proximal signals
remain unknown. Here, we report the fundamental importanceorts 13, 2851–2864, December 29, 2015 ª2015 The Authors 2851
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Figure 1. Tumors Stimulate Autocrine IL-6 and IL-10 in DCs through TLR2
(A) IL-6 and IL-10 production, as measured by ELISA, from WT and Myd88/ mice pre-cDCs stimulated with TCM for 24 hr.
(B) IL-6 and IL-10 production by WT, TLR2/, and TLR4/ mice pre-cDCs incubated in TCM and S17 conditioned medium (S17) for 24 hr.
(C) IL-6 and IL-10 production by WT pre-cDCs cultured in TCM with neutralizing TLR2 mAb or immunoglobulin G1 (IgG1) control (25–100 ng/ml) for 24 hr.
(D) IL-6 and IL-10 production by WT pre-cDCs cultured in TCM, FSL-1 (100 ng/ml), Pam3CSK4 (100 ng/ml), and LPS (1 mg/ml) for 24 hr.
Results are displayed as mean ± SEM and are representative of more than three independent experiments. *p < 0.05; **p < 0.005; ***p < 0.001, determined by
Student’s t test.of TLR2 signaling in driving the differentiation of immunosup-
pressive DCs in cancer.
RESULTS
Tumors Stimulate Autocrine Production of IL-6 and
IL-10 in Pre-cDCs through TLR2
Cancer has no apparent adverse effect on circulating pre-cDCs
(Diao et al., 2010), at least for tumors <1 cm in diameter, suggest-
ing that tumor DC dysfunction is initiated by direct exposure to
the tumor microenvironment. We hypothesized that the immedi-
ate cytokine response of pre-cDCs to tumor-conditioned me-
dium (TCM) might serve as a screening tool to investigate
whether TLR signaling regulates cDC differentiation in cancer.
All TLRs, except TLR3, signal through the adaptor molecule
myeloid-differentiation factor 88 (MyD88) (Yamamoto et al.,
2003). We first cultured wild-type (WT) and MyD88-deficient
spleen pre-cDCs in TCM generated from Lewis lung carcinoma
(LLC), andmeasured IL-6 and IL-10 concentrations in culture su-
pernatants 24 hr later. WT pre-cDCs, but not MyD88/ pre-
cDCs, produced both IL-6 and IL-10 (Figure 1A); neither cytokine
was detectable in TCM alone (data not shown). We obtained
similar results using TCM generated from B16 melanoma.2852 Cell Reports 13, 2851–2864, December 29, 2015 ª2015 The AuTLR2 and TLR4 are well-recognized receptors for danger-
associated molecular patterns (DAMPS) in the tumor microenvi-
ronment (Apetoh et al., 2007). Therefore, we investigated the
response of spleen pre-cDCs from TLR2/ and TLR4/ mice
to TCM. TCM failed to stimulate IL-6 and IL-10 production in
TLR2/ pre-cDCs, whereas pre-cDCs from TLR4/ mice pro-
duced both cytokines at levels similar to that of WT control
(Figure 1B). As expected, control S17 fibroblast-conditioned
medium (S17) stimulated low levels of IL-6 and IL-10 in WT,
TLR2/, and TLR4/ pre-cDCs. We considered whether
a cell-intrinsic defect accounted for the inability of TCM to
stimulate IL-6 and IL-10 in TLR2/ pre-cDCs; however, adding
neutralizing anti-TLR2 antibodies to TCM also inhibited cytokine
production in WT pre-cDCs in a dose-dependent manner
(Figure 1C).
TLR2 forms heterodimers between TLR1 or TLR6 to recognize
diacylated (e.g., FSL-1) or triacylated (Pam3CSK4) lipoproteins,
respectively. Both FSL-1 and Pam3CSK4mimicked TCM in their
ability to stimulate IL-6 and IL-10 by WT pre-cDCs (Figure 1D),
whereas lipopolysaccharide (LPS) only stimulated IL-6. Collec-
tively, these findings indicated that tumor-derived factors stimu-
late production of autocrine IL-6 and IL-10 in pre-cDCs through a
TLR2/MyD88 signaling pathway.thors
A B
C D E F
Figure 2. Tumors Promote Differentiation of IL-10-Producing DCs through TLR2
(A) Production of IL-10, IL-1b, and IL-12p70 byWT and TLR2/ pre-cDCs pretreated with TCM or S17 for 72 hr, then recovered, washed, and recultured for 18 hr
in fresh complete medium containing LPS (10 ng/ml).
(B) IL-10 production by WT pre-cDCs pretreated with TCM, FSL-1, Pam3CSK4, and LPS for 72 hr.
(C) IL-10 production by WT pre-cDCs pretreated with TCM with or without added anti-TLR2 antibodies (25–100 ng/ml) for 72 hr.
(D) IL-10 production by WT pre-cDCs pretreated with TCM in the presence or absence of blocking antibodies to IL-6 (10 mg/ml) and IL-10 (10 mg/ml) for 72 hr.
(E) IL-10 production by WT pre-cDCs pretreated with TCM in the presence or absence of blocking antibodies to TLR2 (100 ng/ml) and exogenous IL-6 and IL-10
(both 1 mg/ml) in the primary culture for 72 hr.
(F) IL-10 production by WT and TLR2/ pre-cDCs pretreated with TCM in the presence or absence of exogenous IL-6 and IL-10 for 72 hr.
Results are displayed as mean ± SEM. **p < 0.005; ***p < 0.001. See also Figure S1.Autocrine IL-6 and IL-10 Promote Differentiation of
IL-10-Producing DCs
Previous studies have shown that, in contrast with spleen DCs,
tumor DCs preferentially produce IL-10 rather than IL-1b and
IL-12 when stimulated with LPS. To determine whether TCM in-
duces this aberrant response in pre-cDCs, we extended the cul-
ture period to 72 hr, recovered and washed the cells extensively,
and stimulated themwith LPS for 18 hr. WT pre-cDCs pretreated
with TCM, but not S17, produced large quantities of IL-10 (Fig-
ure 2A). TLR2 deficiency blocked this response and increased
their capacity to produce both IL-1b and IL-12p70. Pre-cDCs
pretreated with FSL-1 and Pam3CSK4 also produced high
amounts of IL-10, as compared to those pre-treated with LPS,
whereas adding anti-TLR2 antibodies to TCMblocked IL-10 pro-
duction (Figures 2B and 2C).
Next, we investigated the role of TCM-induced autocrine IL-10
and IL-6 in this process. Neutralizing anti-IL-6 or anti-IL-10 anti-
bodies decreased the capacity of TCM to induce IL-10-produc-
ing cDCs from WT pre-cDCs, and blocking both cytokines was
synergistic (Figure 2D). These findings suggested that paracrine
stimulation with IL-10 and IL-6 was sufficient; however, exoge-
nous IL-6 and IL-10 failed to restore IL-10 production completelyCell Repwhen TLR2 was blocked with neutralizing antibodies or was
genetically deficient (Figures 2E and 2F), even though the con-
centration of these cytokines was 2- to 3-fold higher than those
produced by WT pre-cDCs in TCM. Furthermore, adding IL-6
and IL-10 to WT pre-cDCs cultured in Flt3 ligand or S17 medium
for 72 hr failed to generate IL-10-producing DCs (Figures S1A
and S1B). Collectively, these findings suggested that TLR2
signaling engages mechanisms beyond stimulating autocrine
IL-6 and IL-10 to promote DC dysfunction.
TLR2 Ligation Sensitizes DCs to IL-6 and IL-10
Stimulation
We hypothesized that TLR2 signaling might increase the sensi-
tivity of pre-cDCs to IL-6 and IL-10. To explore this idea, we first
measured the expression levels of IL-6Ra and IL-10Ra, the cyto-
kine-binding component of these receptors (Kishimoto, 2005;
Moore et al., 2001). As compared to unstimulated control,
stimulation of WT pre-cDCs with TCM and FSL-1 increased
cell-surface expression of both IL-6Ra and IL-10Ra, whereas
stimulation with S17 and LPS reduced expression levels slightly
(Figures 3A and 3B). Induction of IL-6Ra and IL-10RamRNA, as
measured by quantitative real-time PCR, accompanied IL-6Raorts 13, 2851–2864, December 29, 2015 ª2015 The Authors 2853
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Figure 3. TLR2 Ligation Sensitizes DCs to IL-6 and IL-10 Stimulation
(A and B) Mean fluorescence intensity (MFI) of surface IL-6Ra or IL-10Ra expression by unstimulated DCs or DCs cultured in TCM, with or without neutralizing
anti-TLR2 antibodies (100 ng/ml), S17, FSL-1, and LPS for 18 hr. Results are displayed as mean ± SEM. *p < 0.05; **p < 0.005; ***p < 0.001 by Student’s t test.
(C) Real-time PCR analysis of IL-6Ra (il6ra) and IL-10Ra (il10ra) mRNA in DCs. All values were normalized to gapdh expression, and fold changes are relative to
unstimulated control. Results are displayed as mean ± SEM. **p < 0.005; ***p < 0.001 by Student’s t test.
(D) Intracellular expression of phosphorylated STAT3 (STAT3-pY705) by DCs that were pretreated with TCM or left untreated for 18 hr then stimulated with the
indicated concentrations of IL-6 and IL-10 for 30 min.
(E) STAT3 mRNA expression determined by real-time PCR of DCs cultured for 18 hr with or without TCM. Results are displayed as mean ± SEM.
See also Figures S2 and S3.and IL-10Ra upregulation (Figure 3C). Adding anti-TLR2 anti-
bodies to TCM blocked these responses completely.
Since TCM stimulated secretion of IL-6 and IL-10, we specu-
lated that IL-6Ra and IL-10Ra expression levels were being self-
regulated by their respective cytokine. We found, however, that
TCM continued to induce IL-6Ra and IL-10Ra mRNA and sur-
face receptor expression in the presence of neutralizing anti-
bodies to IL-6 and IL-10 (Figure S2), suggesting that TLR2
signaling increases IL-6Ra and IL-10Ra expression indepen-
dently of its effect on autocrine IL-6 and IL-10 production and
signaling.
STAT3 is the main downstream molecular target for IL-6R and
IL-10R signaling and promotes IL-10 while inhibiting IL-12 pro-
duction in DCs (Kortylewski et al., 2009; Moore et al., 2001). To2854 Cell Reports 13, 2851–2864, December 29, 2015 ª2015 The Audirectly test the functional relevance of increased IL-6Ra and
IL-10Ra expression, we assessed phosphorylated STAT3
(pSTAT3) levels in response to graded concentrations of IL-6
and IL-10. Spleen pre-cDCs from WT mice were cultured in
TCM or control medium for 24 hr, recovered and rested for
4 hr, and then stimulated with IL-6 and IL-10 for 30 min. Before
cytokine stimulation, pre-cDCs cultured in TCM and control me-
dium exhibited similar basal levels of pSTAT3 (Figure 3D). The
threshold IL-6 and IL-10 concentrations that induced pSTAT3
were about 50-fold lower for pre-cDCs cultured in TCM as
compared to control (1 ng/ml versus 50 ng/ml). pSTAT3 expres-
sion peaked at IL-10 and IL-6 concentrations of 100 ng/ml for
both unstimulated and TCM-pretreated DCs; however, at peak
cytokine concentrations, TCM pre-treated DCs achieved higherthors
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Figure 4. Superior Function of Tumor cDCs from TLR2/ Mice
(A) Representative flow cytometric plots showing expression of IL-6Ra, IL-10Ra, and STAT3-pY705 by DCs sorted from B16 tumors and spleens of WT (red line)
and TLR2/ (blue line) mice. Bar graphs show MFI of IL-6Ra, IL-10Ra, and STAT3-pY705 by tumor DCs (n = 3–5 mice per group).
(B) Production of IL-10 and IL-1b by sorted tumor and spleen DCs after overnight culture in LPS (1 mg/ml).
(C) Flow cytometry for the indicated cell-surface molecules.
(D) Stimulation capacity of sorted tumor and spleen DCs from WT and TLR2/ mice in mixed allogeneic lymphocyte reactions.
Results are expressed as mean counts per minute (cpm) 3 103 ± SEM. *p < 0.05; **p < 0.005; ***p < 0.001, determined by Student’s t test.levels of pSTAT3 than control. STAT3 transcription levels in pre-
cDCs pre-treated with TCM remained similar to that of control
(Figure 3E), further supporting the hypothesis that the increased
level of pSTAT3 resulted from increased IL-6 and IL-10 receptor
signaling. Consistent with these findings, the increased expres-
sion levels of IL-6R and IL-10R in pre-cDCs pre-treated with
FSL-1 reduced the concentrations of IL-6 and IL-10 needed to
activate STAT3 (Figure S3). Collectively, these data indicate
that TLR2 activation by tumor-derived factors promotes differen-
tiation of IL-10-producing DCs by increasing the sensitivity of tu-
mor DCs to IL-6 and IL-10 stimulation.
TLR2 Signaling Drives Tumor DC Dysfunction In Vivo
Next, we examined the influence of TLR2 on the expression
levels of IL-6Ra, IL-10Ra, and pSTAT3 in cDCs isolated from
spleen and tumors of mice bearing subcutaneous B16 mela-
noma. WT tumor cDCs displayed increased expression levels
of both cytokine receptors and pSTAT3, as compared to tumor
DCs from TLR2/ mice (Figure 4A). Spleen DCs from tumor-
bearing WT and TLR2/ mice expressed similar low levels of
IL-6Ra, IL-10Ra, and pSTAT3.
To determine whether these altered cytokine receptor and
pSTAT3 expression levels correlate with DC function, we sorted
cDCs from tumors and the spleen of tumor-bearing WT andCell RepTLR2/ mice and compared their ability to produce IL-10 and
IL-1b after LPS stimulation (Figure 4B). As expected, spleen
DCs from both WT and TLR2/ mice produced high and low
amounts of IL-1b and IL-10, respectively (He et al., 2013). WT tu-
mor DCs produced high amounts of IL-10 and no IL-1b, whereas
tumor cDCs from TLR2/ mice produced IL-10 and IL-1b at
levels similar to that of spleen cDCs.
Tumor cDCs from TLR2/mice also displayed higher expres-
sion levels of cell-surface MHC II, CD40, and CD86 (Figure 4C)
and stimulated proliferation of allogeneic lymphocytes more
effectively than those from WT mice, consistent with a higher
level of maturation or activation (Figure 4D). Collectively, these
findings indicated that TLR2 deficiency inhibits the ability of
the tumor milieu to upregulate IL-6Ra and IL-10Ra, activate
STAT3, and impair the function of tumor cDCs. By contrast,
spleen DCs in TLR2/ mice remain similar to those in WT
mice, which supports the view that DC dysfunction in B16-
bearing mice occurs predominately in the cancer.
TLR2 Deficiency Improves T Cell Responses to
Anti-cancer Vaccine
To test whether the improved function of tumor cDCs would
enhance anti-tumor immunity, we compared the efficacy of
an irradiated B16 melanoma vaccine engineered to expressorts 13, 2851–2864, December 29, 2015 ª2015 The Authors 2855
AB
C
Figure 5. TLR2 Deficiency Improves Tumor Vaccination
(A) Relative growth of subcutaneous B16 melanoma in untreated and GVAX-treated WT and TLR2/ mice. GVAX treatment schedule is indicated in the
schematic. Results are displayed as mean ± SEM with 13 mice per group. *p < 0.05, by unpaired Mann-Whitney test.
(legend continued on next page)
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granulocyte/macrophage colony-stimulating factor (GM-CSF)
(GVAX) in WT and TLR2/ mice bearing established B16
melanoma (Figure 5A). Tumor growth rateswere similar in unvac-
cinated WT and TLR2/ mice, consistent with the poor immu-
nogenicity of B16 melanoma (Dranoff, 2012). In agreement with
previous reports, GVAX alone had no effect on tumor growth in
WT mice (van Elsas et al., 1999). By contrast, GVAX suppressed
tumor growth significantly in TLR2/ mice.
Flow cytometric analysis of the tumors revealed that GVAX im-
munization in TLR2/mice was associated with a significant in-
crease in the frequency CD3+ T cells, CD8+ T cells, and CD4+
T cells, whereas the frequencies of these populations were
similar in vaccinated and unvaccinated WT mice. (Figure 5B).
We found no difference in the frequencies of Foxp3+ T regulatory
cells (Tregs) and gd T cells after GVAX in WT or TLR2/ mice.
The frequency of natural killer (NK) cells was higher in vaccinated
TLR2/ mice than in WT mice. Analysis of the corresponding
lymphoid populations in spleen showed no differences in the
four groups of mice (data not shown), indicating that the absence
of TLR2 signaling did not have a systemic effect in the lymphoid
compartment.
We also analyzed tumor DC subsets and other myeloid popu-
lations. The frequency of intra-tumor CD103+ cDCs, which have
a proclivity for cross-presentation of tumor-derived antigens to
T cells, can influence the efficacy of anti-tumor immune re-
sponses and tumor growth (Broz et al., 2014; Ruffell et al.,
2014). Assessment of the frequency of CD11chiMHC IIhi cDC
subpopulations in WT and TLR2/mice according to the gating
schema—DC1 (CD103+CD11b), DC2 (CD103CD11b+CD64
F4/80), and DC3 (CD103CD11b+CD64+F4/80+)—showed no
differences in tumors and spleen (spleen DC1s are CD8+
CD11b) (Figure 5C; Figure S4). pDCs exist in trace numbers
in B16 melanoma and were not compared. Tumor-infiltrating
macrophages and neutrophils can both support and suppress
anti-tumor T cell responses (Gabrilovich et al., 2012). We de-
tected no difference in the frequency of macrophages/mono-
cytes (F4/80+CD11b+MHCII) and neutrophils (Ly6G+). Notably,
the frequency of myeloid-derived suppressor cells (MDSC), as
defined by LinCD11b+Gr-1+, was also similar in WT and
TLR2/ mice (Figure S5).
Thus, the anti-tumor effects of GVAX in TLR2/ mice corre-
lated with the intra-tumor frequency of T cells and, to a lesser
extent, with NK cells but not with the frequency of Tregs, DC sub-
sets, or MDSC.
TLR2 Deficiency Enhances Anti-tumor CTL Responses
in Tumors
Both T cell priming in lymphoid tissues and cognate interactions
with intra-tumor DCs contribute to T cell expansion in tumors
(Broz et al., 2014; Diao et al., 2011; Kerkar et al., 2011; Ma
et al., 2013). Since the function and frequencies of spleen DCs
were similar in WT and TLR2/ mice (Figure 4), it seemed un-(B) Flow cytometric quantitation of lymphoid cell populations in B16 melanoma. R
Whitney test; NS, not significant.
(C) Flow cytometric quantitation of DCs, neutrophils and monocyte/macrophages
DC1 (CD103+CD11b), DC2 (CD103CD11b+CD64F4/80), and DC3 (CD103
Results are displayed as mean ± SEM. See also Figures S4–S6.
Cell Replikely that differences in T cell priming would account for the
increased frequency of intra-tumor T cells. Further examination
of lymphoid DCs in GVAX-treated mice revealed no difference
in the frequencies of resident and migrated lymph node DCs;
surface expression levels of CD40, CD80, and CD86; or T cell
stimulation capacity (Figure S6). Consistent with these findings,
we found that the frequency of primed T cells in lymphoid tissues
using an in vitro antigen-recall assay was indistinguishable inWT
and TLR2/ mice (data not shown).
To eliminate the possibility that TLR2 signaling might affect
T cell survival/proliferation (Quigley et al., 2009), and to facilitate
the study of tumor-specific CTL responses in situ, we injected
antigen-activated CD45.1 OT-I CTLs intravenously into CD45.2
WT and TLR2/ mice bearing established B16 (control) or B16
tumors expressing OVA (B16-OVA) and recovered the tumors
3 days later, when they were 1 cm in diameter, for analysis.
As expected, B16 tumors contained fewOT-I CTLs. B16-OVA tu-
mors from TLR2/ mice contained a 5- to 10-fold higher fre-
quency of OT-I CTLs than those from WT mice (Figures 6A and
6B). In addition, almost 50% of these cells expressed interferon
(IFN)-g after re-stimulation with SIINFEKL peptides as compared
to <10% in WT mice (Figure 6C), consistent with more robust
effector activity. The spleen and non-draining lymph nodes of tu-
mor-bearing TLR2/ andWTmice contained a low frequency of
OT-I CTL, regardless of tumor OVA expression (data not shown).
We and others reported previously that tumor DCs possess
the unique ability to stimulate proliferation of tumor-antigen-spe-
cific CTLs, even in the presence of other tumor-infiltrating cells,
including MDSC, monocytes, and macrophages (Broz et al.,
2014; Diao et al., 2011). Since the frequency of CTLs in lymphoid
tissues was similar to that in WT and TLR2/ mice, we hypoth-
esized that the higher intra-tumor CTL frequency in TLR2/
mice was due to increased CTL proliferation within the tumor
(Thompson et al., 2010). To monitor cell division, we injected
CFSE-labeled OT-I CTL into tumor-bearing mice and assessed
tumors and lymphoid tissues 5 days later (Figure 6D). OT-I CTL
divided more extensively in B16-OVA tumors from TLR2/
mice than from WT mice, as measured by CFSE dilution. In
both WT and TLR2/ mice, low levels of OT-I CTL proliferation
occurred in B16-OVA tumor-draining lymph nodes, whereas
non-draining lymph nodes and spleen contained no divided
OT-I CTL. In the absence of OVA, OT-I CTL did not divide in
any of the tissues examined. These findings support the view
that CTL proliferation and acquisition of effector functions within
the tumor regulate anti-tumor T cell responses in TLR2/mice.
To evaluate whether the increased intra-tumor frequency of
CTL in TLR2/ mice affects tumor growth, we transferred
OT-I CTL into TLR2/ and WT mice 3 days after B16-OVA or
B16 inoculation. Analysis of tumor growth rates revealed
enhanced efficacy of OT-I CTL therapy in TLR2/ mice com-
pared to WT mice bearing B16-OVA tumors (Figure 6E). Without
CTL therapy, tumors grew at similar rates in WT and TLR2/esults are displayed as mean ± SEM. *p < 0.05; **p < 0.005, by unpaired Mann-
in B16 melanoma and spleen. DCs were separated into three subpopulations:
CD11b+CD64+F4/80+). DC1s in spleen are CD8+ rather than CD103+.
orts 13, 2851–2864, December 29, 2015 ª2015 The Authors 2857
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Figure 6. TLR2 Deficiency Enhances the Expansion and Function of Transferred Tumor-Antigen-Specific CTLs
(A and B) Frequency of OT-I CTLs in B16 and B16-OVA tumors 3 days after adoptive transfer of CD45.1 OT-I CTL into WT and TLR2/mice. Numbers in the dot
plots indicate percentage of CD45.1+ CD8+ cells in B16 and B16-OVA tumors.
(C) Frequency of CD45.1+ IFNg+ CD8+ T cells in B16 and B16-OVA tumors of WT or TLR2/ mice.
(D) CFSE dilution of CD45.1+ OT-I CTL analyzed 5 days after transfer into WT and TLR2/ mice bearing B16 or B16-OVA tumors. dLN, draining lymph nodes.
(E) Adoptive CTL therapy in WT versus TLR2/ mice inoculated with 0.5 3 106 B16 or B16-OVA cells. Graph shows mean tumor growth.
(F) Adoptive CTL therapy in WT mice inoculated with 1 3 106 B16-OVA cells and treated with a-TLR2 (1 mg/kg) or control IgG antibodies, as indicated.
Results in (B) and (C) are displayed as mean ± SEM. **p < 0.005; ***p < 0.001. See also Figure S7.
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mice. Collectively, these data suggest that the improved function
of tumor cDCs in TLR2/ mice increased the expansion and
functional activity of adoptively transferred CTL.
We also determined whether TLR2 could be targeted in vivo
with neutralizing antibodies as an adjunct for CTL immuno-
therapy. We confirmed that a single intravenous injection of
anti-TLR2 antibodies (1 mg/kg) inhibited Pam3CSK4-induced
cytokine secretion in recovered splenocytes for at least 2 days
(data not shown) (Meng et al., 2004). We found that anti-TLR2
antibody therapy boosted the efficacy of adoptive CTLs signifi-
cantly (Figure 6F).
Published reports indicate that B16 melanoma express TLR2
by qPCR (Oldford et al., 2010; Yang et al., 2009), which raised
the possibility that anti-TLR2 antibodies might influence their
behavior directly. However, we found that, in contrast with sple-
nocytes, B16 melanoma cells neither express TLR2 on their cell
surface nor produce IL-6 and IL-10 when stimulated with
Pam3CSK4 or FSL-1 (Figure S7). Consistent with these findings,
a short course of anti-TLR2 therapy alone had no effect on tumor
growth (Figure 6F). Thus, the benefit of blocking TLR2 signaling
on CTL therapy does not depend on TLR2 expression in B16
melanoma.
Human Cancers Induce Human DC Dysfunction
through TLR2
Next, we addressed whether TLR2 affects the response of hu-
man DCs to human cancers. We measured IL-6 and IL-10 pro-
duction by monocyte-derived human DCs incubated for 24 hr
in conditioned medium generated from lung (H-125) and liver
(HepG2) cancer cell lines, primary colon cancer cells (Colon
328), and control human spleen fibroblasts (FCM). As compared
to unstimulated control, TCM from all three cancers stimulated
autocrine production of IL-6 and IL-10 (Figure 7A), which was in-
hibited by the addition of anti-TLR2 antibodies to the culture me-
dium (Figure 7B). FCM stimulated no IL-10 and little IL-6, which
was blocked by anti-TLR2 antibodies. Further analysis of the ef-
fects of H-125-TCM on human DCs showed that it increased the
surface expression of IL-6Ra and IL-10Ra, as well as the mRNA
levels for these receptors (Figures 7C and 7D).
We also found that H-125 downregulated cell-surface expres-
sion of major histocompatibility complex class II (MHC II) and
CD86 (Figure 7E) and induced the differentiation of IL-10-
producing DCs, as detected by LPS stimulation in secondary
cultures (Figures 7F). Anti-TLR2 antibodies blocked these
changes and restored the production of IL-1b and IL-12p70
to levels similar to those produced by DCs that were main-
tained in GM-CSF. Furthermore, anti-TLR2 antibodies improved
their stimulatory capacity in mixed allogeneic lymphocyte reac-
tions (Figure 7G). Collectively, these data indicate that the mech-
anisms mediating DC dysfunction in mice also operate in
human DCs.
Tumor-Derived Versican Induces cDC Dysfunction
Versican, an ECM proteoglycan that is upregulated in many can-
cers, activates macrophages through TLR2 to secrete tumor ne-
crosis factor (TNF) and IL-6 (Kim et al., 2009). Accordingly, we
speculated that versicanmay trigger DC dysfunction. Consistent
with this possibility, the addition of anti-versican antibodies toCell RepTCM decreased IL-6 and IL-10 secretion by pre-cDCs at 24 hr,
whereas the addition of antibodies to high mobility group box 1
(HMGB1), a pro-inflammatory TLR4 ligand released by dying
cancer cells (Apetoh et al., 2007), inhibited neither IL-6 nor
IL-10 secretion (Figure S8A). To further investigate the role of
versican, we generated TCM from LLC cells transducedwith ver-
sican and control short hairpin RNA (shRNA) (Figures S9A and
S9B). Versican knockdown decreased the capacity of TCM to
stimulate IL-6 and IL-10 production in pre-cDCs at 24 hr (Fig-
ure S8B); and cells recovered and re-stimulated with LPS at
72 hr showed a lower and higher capacity to produce IL-10
and IL-12p70, respectively. These results mirrored those ob-
tainedwith the addition of anti-TLR2 antibodies to control shRNA
TCM (Figure S8C), supporting the view that versican is a key
TLR2 ligand in LLC TCM.
Next, we analyzed the in vivo effect of tumor-derived versican
on tumor DCs. LLC transducedwith versican-shRNA and control
shRNA were inoculated into B6 mice subcutaneously; both
tumors grew at a similar rate, as reported previously (Kim
et al., 2009).We detected 4-fold higher expression levels of intra-
cellular IL-12 p40 in DCs isolated from versican knockdown tu-
mors as compared to those from control tumors (Figure S8D).
The frequency of tumor DC subsets was similar in control- and
versican-knockdown tumors (Figure S9). Collectively, these
data suggest that tumor-derived versican promotes tumor DC
dysfunction.
DISCUSSION
In this study, we show that TLR2 activation is a critical proximal
signal leading to DC dysfunction in cancer. TLR2 ligation not only
stimulated secretion of autocrine IL-10 and IL-6 but also,
perhaps more importantly, led to sustained elevation of the
cell-surface receptors for these cytokines, which decreased
the threshold concentration required to activate STAT3. This
feed-forward amplification loop reprogramed DCs to produce
high amounts of IL-10 rather than IL-12 and IL-1b when stimu-
lated with LPS, a classic pro-inflammatory stimulus. We found
that tumor-derived versican can trigger this pathway. TLR2 defi-
ciency improved the immunogenicity of intra-tumor DCs and
enhanced expansion and proliferation and CTLs in tumors,
acquisition of CTL effector functions, and anti-tumor responses.
Earlier studies established a linkage between STAT3, tumori-
genesis, and impairment of anti-tumor immunity (Yu et al.,
2007). Elevated STAT3 activity in tumor DCs is ascribed mostly
to paracrine stimulation by tumor-derived cytokines such as
IL-6, IL-10, and VEGF (Lee et al., 2010; Nefedova et al., 2004;
Wang et al., 2004), although macrophages and other tumor-
infiltrating cell populations can also produce these cytokines
(Ruffell et al., 2014). Our study reveals the previously unrecog-
nized role of autocrine cytokines induced by TCM in causing
DC dysfunction. We found that both IL-6 and IL-10 were key to
this process and behaved synergistically. Although typically
considered a pro-inflammatory cytokine, IL-6 dampens immune
responses in some settings (Hunter and Jones, 2015; Mauer
et al., 2014). TCM also stimulates the release of IL-1b from
pre-cDCs; however, neutralizing anti-IL-1b fails to prevent the
subsequent differentiation of IL-10-producing DCs (M.S.C. andorts 13, 2851–2864, December 29, 2015 ª2015 The Authors 2859
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Figure 7. Human Cancers Induce Human DC Dysfunction through TLR2
(A) IL-6 and IL-10 production by human DCs unstimulated (US) or cultured for 24 hr in conditioned medium (CM) derived from FCM, NCI-H125, HepG2, and
Colon328.
(B) IL-6 and IL-10 production by human DCs under the same conditions as in (A) in the presence of anti-TLR2 (10 mg/ml) blocking antibodies or control IgG2b
antibodies.
(C) Surface expression of IL-6Ra and IL-10Ra at 24 hr human DCs unstimulated (US) or cultured for 24 hr in conditioned medium derived from NCI-H125.
(D) IL-6Ra and IL-10Ra mRNA expression at 24 hr determined by quantitative real-time PCR. Fold change is relative to unstimulated control.
(E) Flow cytometric analysis of HLA-DR and CD86 expression of human DCs cultured for 48 hr in GM-CSF, FCM, or NCI-H125 TCM with or without anti-TLR2
antibodies.
(F) IL-10, IL-1b, and IL-12p70 production by human DCs pretreated with NCI-HI25 TCM and FCM or left in GM-CSF for 72 hr and then washed and restimulated
with LPS for 18 hr.
(G) Stimulation capacity of human DCs cultured as in (E) in mixed allogeneic lymphocyte reactions.
Results are displayed as mean ± SEM and are representative of three independent experiments. *p < 0.05; **p < 0.005; ***p < 0.001, assessed by unpaired
Student’s t tests.M.T., unpublished data). Although autocrine IL-6 and IL-10medi-
ated DC dysfunction in vitro, the relative importance of autocrine
versus paracrine signaling in vivo remains unclear.
The intensity and duration of STAT3 signaling governs whether
an anti-inflammatory signal is delivered to DCs (Braun et al.,
2013; Yasukawa et al., 2003). We show that IL-10R and IL-6R
expression levels calibrate the sensitivity of DCs to IL-10 and
IL-6 based on their ability to activate STAT3. TLR2 ligation2860 Cell Reports 13, 2851–2864, December 29, 2015 ª2015 The Auincreased expression levels IL-6R and IL-10R independently of
IL-6 and IL-10 signaling. In the absence of receptor upregulation,
the capacity of paracrine IL-6 and IL-10 to induce STAT3 and DC
dysfunction was diminished markedly. Thus, TLR2 ligation im-
prints the capacity to respond to lower concentrations of these
cytokines, which helps explain the relative tumor specificity of
DC dysfunction. These findings also suggest that cytokine re-
ceptor expression levels, rather than the source of the cytokinesthors
per se, may be the ultimate arbiter of DC fate and function in vivo.
In support of this theory, a recent study found that IL-10R
expression was absolutely required for intestinal macrophages
to prevent spontaneous colitis, whereas autocrine IL-10 was
dispensable (Zigmond et al., 2014).
Tumor DCs from TLR2/ mice exhibited several key attri-
butes of effective antigen-presenting cells: (1) high expression
levels of MHC II and co-stimulatory molecules; (2) expression
of pro-inflammatory IL-1b rather than IL-10; and (3) potent stim-
ulation of allogeneic lymphocytes. These functional properties
correlated with better anti-tumor immune responses elicited by
a GVAX vaccine and higher rates of proliferation and expression
of IFN-g in adoptively transferred OT-1 CTL. Since other tumor-
infiltrating immune cells express TLR2, we cannot exclude the
possibility that the absence of TLR2 signaling in these cells
also influenced anti-tumor immune responses. It is noteworthy,
however, that growing evidence points to a unique role for tumor
DCs in regulating the proliferation, expansion, and function of tu-
mor-infiltrating CTLs through cross-presentation of acquired tu-
mor antigens (Broz et al., 2014; Broz and Krummel, 2015; Diao
et al., 2011; Ma et al., 2013). This role for tumor DCs aligns
well with the function of tissue DCs in restimulating effector
and memory T cells in situ (McGill et al., 2008; Wakim et al.,
2008).
TLR2 signaling can increase CD8+ T cell effector activity and
survival and reduce the suppressive function of Tregs (Geng
et al., 2010). In our study, GVAX immunization in TLR2/ mice
resulted in higher frequencies of intra-tumor CD8+ T cells and
no difference in the frequency of Foxp3+ Tregs, as compared
to those in WT mice. We propose that the immunologic benefit
of blocking TLR2 signaling in tumor DCs in B16 melanoma out-
weighs the loss of TLR2 signaling in T cells. This dynamic may
vary in different tumors, which may explain why TLR2 agonists
have been reported to both promote and inhibit tumor growth
(Huang et al., 2007; Zhang et al., 2011). In some tumors, TLR2
signaling directly contributes to tumorigenesis and tumor cell
proliferation and survival (Tye et al., 2012). In our study, we failed
to detect cell-surface expression of TLR2 or a functional
response to TLR2 agonists in B16 cells.
Recent reports suggest that particular DC subpopulations are
particularly well equipped to promote anti-tumor immunity. Tu-
mor CD103+ DCs, which are linked ontogenetically to spleen
CD8+ DCs (Hildner et al., 2008), express higher levels of IL-12
and stimulate T cells more effectively than tumor CD11b+ DCs
(Broz et al., 2014). Indirect or direct inhibition of tumor macro-
phage-derived IL-10 (anti-CSF and anti-IL-10R antibodies,
respectively) increased the density of tumor CD103+ DCs, which
correlated with a better response to paclitaxel in a spontaneous
breast cancer model (Ruffell et al., 2014). In our study, TLR2 defi-
ciency had no effect on the frequencies of cDC subpopulations;
and all populations displayed a similar increase in the expression
levels of MHC II and co-stimulatory molecules as compared to
tumor DCs from WT mice. Although CD11b+ DCs are less effec-
tive antigen-presenting cells than CD103+ DCs on a per-cell ba-
sis, they have a substantial numerical advantage in most tumors
and likely contribute to anti-tumor immunity. Indeed, depletion of
tumor CD11b+ DCs abolished the efficacy of chemotherapy-
induced anti-tumor T cell responses (Ma et al., 2013).Cell RepHuman and mouse tumors produce a variety of TLR2 ligands,
including versican, laminin-b1, procollagen III-a1, Hsp60, and
Hsp72 (Chalmin et al., 2010; Kim et al., 2009; Yang et al.,
2009). The microbiome also generates TLR2 ligands that could
potentially influence the tumormicroenvironment and tumor pro-
gression (Schwabe and Jobin, 2013). This panoply of TLR2 li-
gands suggests that targeting the receptor rather than individual
ligands may be a more effective strategy to modulate anti-tumor
immunity. The tumor microenvironment also produces immu-
nostimulatory molecules, such as HMGB1 (a TLR4 ligand) and
ATP (Apetoh et al., 2007; Ghiringhelli et al., 2009). How tumor
DCs respond to ostensibly conflicting signals merits further
investigation. Our findings raise the possibility that treatments
aimed to stimulate the release TLR4 ligands in tumors may
augment IL-10 production from ‘‘re-programmed’’ DCs.
Immunotherapy offers great potential for long-term cure and
survival for cancer patients (Rosenberg et al., 2008). Advances
in understanding T cell biology has led to new approaches to
increase the efficacy of immunotherapy, including cytokine ther-
apy (e.g., IL-2, IL-7, and IL-15) and blockade of regulatory mole-
cules (CTLA-4/CD28, PD1/PD-L1) and immunosuppressive cells
(Tregs) (Mellman et al., 2011). Although the success rates of
immunotherapy continue to improve and there are examples of
spectacular responses, this therapy is not consistently effective,
and many patients derive little or no benefit (Restifo et al., 2012).
Our study suggests that targeting TLR2 to prevent tumor DC
dysfunction may be a practical adjunct to improve the results
of immunotherapy.
EXPERIMENTAL PROCEDURES
Mice
Male C57BL/6, BALB/c, TLR2/, TLR4/, and OT-I mice and C57BL/6.SJL
(CD45.1) congenic mice were purchased from The Jackson Laboratory or
Taconic Farms and bred in our animal facility. MyD88/ mice were provided
by Dr. Peter Liu (University of Toronto). Mice were maintained in pathogen-
free conditions in accordance with University Health Network Animal
Resource Center guidelines and used at 2–3 months of age. The Animal
Research Committee of University Health Network reviewed and approved
the studies.
Tumor Models
B16-F10 melanoma (B16), LLC, and human cancer cell lines were purchased
from the American Type Culture Collection. B16-OVA was kindly provided by
R.W. Dutton at the Trudeau Institute (Dobrzanski et al., 2004). Primary colon
cancer cells were kindly provided by C. O’Brien (Ontario Cancer Institute).
To establish tumors, 0.5–13 106 B16 or B16-OVA tumor cells in 100 ml PBS
were injected subcutaneously (s.c.) into the flank of C57BL/6 mice. Tumor di-
mensions were measured with calipers, and tumor size was calculated by
multiplying 2/3 length and width.
Cell Isolation
Single-cell suspensions generated from tumors, spleen, and lymph nodes
were prepared and analyzed as described in the Supplemental Experimental
Procedures.
Flow Cytometry
Cell suspensions were preincubated with anti-CD16/32 to block Fc receptors
and then were washed and incubated with the indicated monoclonal antibody
(mAb) conjugates for 30 min at 4C in a final volume of 100 ml PBS containing
0.5% BSA and 2 mM EDTA. In all experiments, appropriate control isotype
matched mAbs were included to determine the level of background staining.orts 13, 2851–2864, December 29, 2015 ª2015 The Authors 2861
For intracellular cytokine detection, surface antibody-labeled cells were fixed,
permeabilized, and stained with anti-cytokine antibodies according to the in-
structions from the BD Cytofix/Cytoperm Kit (BD Biosciences). The antibodies
and reagents are described in detail in the Supplemental Experimental
Procedures.
Preparation of Conditioned Medium
Cancer cell lines, S17 cells (a kind gift from K. Dorshkind, David Geffen School
of Medicine at UCLA), and human spleen-derived fibroblasts were cultured at
90% confluence in serum-free medium for 20–24 hr. Supernatants were
filtered through a 0.22-mm filter, stored at 80C, and thawed immediately
before use as described in the Supplemental Experimental Procedures.
Cytokine Assays
IL-6, IL-1b, IL-10, and IL-12p70 concentrations were measured by ELISA with
commercial kits (OptEIA; BD Biosciences). Notably, mouse pre-cDCs do not
require pre-treatment with a caspase activator to produce IL-1b (He et al.,
2013).
Gene Expression Analysis
Total cell RNA was prepared from DCs with the RNAeasy Kit (QIAGEN), fol-
lowed by first-strand cDNA synthesis using M-MLV Reverse Transcriptase (In-
vitrogen). qPCR for IL-6R, IL-10R, and STAT3 gene expression was performed
as described in the Supplemental Experimental Procedures.
Versican Knockdown with Lentiviral Transduction
Versican shRNA (SHCLNG-NM_004385) and control shRNA (SHC016) con-
structs were purchased from Sigma-Aldrich and packaged into lentivirus vec-
tors in our laboratory. LLC and B16 cells were incubated with lentivirus culture
supernatants containing polybrene (10 mg/ml) for 48 hr and selected in the
presence of puromycin (1 mg/ml; Invivogen). Knockdown of versican expres-
sion was verified by quantitative real-time PCR and western blot.
Statistical Analysis
Results are expressed as means ± SEM and mean ± SD. Data were analyzed
by Student’s t test, Mann-Whitney test, two-way ANOVA, and the log-rank
test. The analyses were performed with the GraphPad Prism statistical pro-
gram. p values < 0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and nine figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.11.053.
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